Literature DB >> 15518802

Reengineering paramyxovirus tropism.

Elizabeth M Hadac1, Kah-Whye Peng, Takafumi Nakamura, Stephen J Russell.   

Abstract

Receptor specificity is a critical determinant of viral tropism, but the capacity of viruses to switch to alternative receptors has not been extensively studied. Here, we engineered the attachment protein of an attenuated measles virus and generated truly retargeted viruses that are blind to the native receptors CD46 and SLAM, but which propagate efficiently and exclusively via alternative cellular receptors, epidermal growth factor receptor, or CD38. The engineered receptor tropisms were stably maintained during multiple serial virus passage without reversion to native receptor usage, even on cells offering the choice of both native and alternative receptors. We conclude that paramyxoviruses have a remarkably flexible and adaptable entry mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15518802     DOI: 10.1016/j.virol.2004.08.036

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  34 in total

1.  Oncolytic measles virus retargeting by ligand display.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Stephen J Russell; Evanthia Galanis
Journal:  Methods Mol Biol       Date:  2012

2.  Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Authors:  Amber Miller; Rebecca Nace; Camilo Ayala-Breton C; Michael Steele; Kent Bailey; Kah Whye Peng; Stephen J Russell
Journal:  Mol Ther       Date:  2015-12-09       Impact factor: 11.454

3.  Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.

Authors:  Vittal V S Kurisetty; Joshua Heiber; Rae Myers; Guilherme S Pereira; Jarrard W Goodwin; Mark J Federspiel; Stephen J Russell; Kah Whye Peng; Glen Barber; Jaime R Merchan
Journal:  Head Neck       Date:  2014-02-01       Impact factor: 3.147

Review 4.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.

Authors:  Weiwei Shen; Mrinal M Patnaik; Autumn Ruiz; Stephen J Russell; Kah-Whye Peng
Journal:  Blood       Date:  2015-12-28       Impact factor: 22.113

6.  Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Marshall Behrens; Rebecca Nace; Shruthi Naik; Mark J Federspiel; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2016-09-26       Impact factor: 11.454

7.  Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.

Authors:  D Dingli; C Offord; R Myers; K-W Peng; T W Carr; K Josic; S J Russell; Z Bajzer
Journal:  Cancer Gene Ther       Date:  2009-06-05       Impact factor: 5.987

8.  Affinity thresholds for membrane fusion triggering by viral glycoproteins.

Authors:  Kosei Hasegawa; Chunling Hu; Takafumi Nakamura; James D Marks; Stephen J Russell; Kah-Whye Peng
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

9.  Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.

Authors:  Stephanie K Carlson; Kelly L Classic; Elizabeth M Hadac; David Dingli; Claire E Bender; Bradley J Kemp; Stephen J Russell
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

10.  Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.

Authors:  Laura Menotti; Arianna Cerretani; Hartmut Hengel; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.